ArticlePituitary2026
Revival of neurophysin-I as a complementary biomarker for circulating oxytocin.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is renewed interest in oxytocin (OXT) associated neurophysin-I (NP-I) as a surrogate biomarker of endogenous OXT secretion into circulation. OXT measurement in humans remains challenging because current assays vary in their specificity for free and protein-bound OXT, and OXT-related peptide species, including extended forms and peptide fragments, and results are influenced by sample handling and analytical methods. NP-I, a carrier protein that is co-synthesized and co-secreted with OXT, can be measured using a validated sandwich immunoassay without extraction. Studies support NP-I as a promising marker of OXT release to circulation, although it is not a replacement for direct OXT measurement. This Editorial reviews the biological relationship between OXT and NP-I, discusses the advantages and limitations of NP-I as a biomarker, and highlights future opportunities for integrating NP-I measurement with advances in OXT assay methodology to improve understanding of the human OXT system in health and disease.
Indexed as
Identifiers
42622891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.